[
  {
    "ts": "2025-11-07T05:32:46+00:00",
    "headline": "The Top 5 Analyst Questions From AbbVie’s Q3 Earnings Call",
    "summary": "AbbVie’s third quarter results were marked by strong year-on-year revenue growth, driven primarily by continued momentum in its immunology and neuroscience portfolios. Management pointed to sales growth from Skyrizi and Rinvoq, as well as double-digit expansion in neuroscience products, as key contributors to the performance. However, despite surpassing Wall Street revenue and profit estimates, the market reacted negatively, reflecting heightened concern over a sharp drop in operating margin and",
    "url": "https://finance.yahoo.com/news/top-5-analyst-questions-abbvie-053246898.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "1c91a2a1-7207-3dbc-8913-6b88baae32a9",
      "content": {
        "id": "1c91a2a1-7207-3dbc-8913-6b88baae32a9",
        "contentType": "STORY",
        "title": "The Top 5 Analyst Questions From AbbVie’s Q3 Earnings Call",
        "description": "",
        "summary": "AbbVie’s third quarter results were marked by strong year-on-year revenue growth, driven primarily by continued momentum in its immunology and neuroscience portfolios. Management pointed to sales growth from Skyrizi and Rinvoq, as well as double-digit expansion in neuroscience products, as key contributors to the performance. However, despite surpassing Wall Street revenue and profit estimates, the market reacted negatively, reflecting heightened concern over a sharp drop in operating margin and",
        "pubDate": "2025-11-07T05:32:46Z",
        "displayTime": "2025-11-07T05:32:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "ABBV Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K222hrzb0FJJlqrDZzsz7w--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cD3IChyAhZhexmnMXW7jMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-5-analyst-questions-abbvie-053246898.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-5-analyst-questions-abbvie-053246898.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]